Martijn Negen joined AM-Pharma in May 2021 with over 20 years in pharmaceuticals, biotechnology and diagnostics companies, ranging from large to start-up.
He brings experience from a variety of local, regional and global commercial leadership roles; focusing on life saving, hospital based medications. In his last assignment, he was General Manager at Portola Pharmaceuticals (acquired by Alexion Pharmaceuticals), leading the launch of Ondexxya (andexanet alfa, a critical care hospital product) in the Nordics, Benelux and Alpine region. Prior to that Martijn held various commercial leadership and general management roles with companies including at Genentech, Astra-Zeneca and Teva Pharmaceuticals and also co-founded NLC, the European HealthTech Venture Builder.
Martijn holds an MBA from Pepperdine University, LA, USA and an MSc in Medical Biotechnology from DeMontfort University in Leicester